These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 31717385

  • 1. Evaluation of NV556, a Novel Cyclophilin Inhibitor, as a Potential Antifibrotic Compound for Liver Fibrosis.
    Simón Serrano S, Grönberg A, Longato L, Rombouts K, Kuo J, Gregory M, Moss S, Elmér E, Mazza G, Gallay P, Pinzani M, Hansson MJ, Massoumi R.
    Cells; 2019 Nov 08; 8(11):. PubMed ID: 31717385
    [Abstract] [Full Text] [Related]

  • 2. Comparison of murine steatohepatitis models identifies a dietary intervention with robust fibrosis, ductular reaction, and rapid progression to cirrhosis and cancer.
    Wei G, An P, Vaid KA, Nasser I, Huang P, Tan L, Zhao S, Schuppan D, Popov YV.
    Am J Physiol Gastrointest Liver Physiol; 2020 Jan 01; 318(1):G174-G188. PubMed ID: 31630534
    [Abstract] [Full Text] [Related]

  • 3. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis.
    Witek RP, Stone WC, Karaca FG, Syn WK, Pereira TA, Agboola KM, Omenetti A, Jung Y, Teaberry V, Choi SS, Guy CD, Pollard J, Charlton P, Diehl AM.
    Hepatology; 2009 Nov 01; 50(5):1421-30. PubMed ID: 19676126
    [Abstract] [Full Text] [Related]

  • 4. Polaprezinc attenuates liver fibrosis in a mouse model of non-alcoholic steatohepatitis.
    Sugino H, Kumagai N, Watanabe S, Toda K, Takeuchi O, Tsunematsu S, Morinaga S, Tsuchimoto K.
    J Gastroenterol Hepatol; 2008 Dec 01; 23(12):1909-16. PubMed ID: 18422963
    [Abstract] [Full Text] [Related]

  • 5. Growth differentiation factor 15 ameliorates nonalcoholic steatohepatitis and related metabolic disorders in mice.
    Kim KH, Kim SH, Han DH, Jo YS, Lee YH, Lee MS.
    Sci Rep; 2018 May 01; 8(1):6789. PubMed ID: 29717162
    [Abstract] [Full Text] [Related]

  • 6. Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation.
    Bates J, Vijayakumar A, Ghoshal S, Marchand B, Yi S, Kornyeyev D, Zagorska A, Hollenback D, Walker K, Liu K, Pendem S, Newstrom D, Brockett R, Mikaelian I, Kusam S, Ramirez R, Lopez D, Li L, Fuchs BC, Breckenridge DG.
    J Hepatol; 2020 Oct 01; 73(4):896-905. PubMed ID: 32376414
    [Abstract] [Full Text] [Related]

  • 7. Metformin ameliorates activation of hepatic stellate cells and hepatic fibrosis by succinate and GPR91 inhibition.
    Nguyen G, Park SY, Le CT, Park WS, Choi DH, Cho EH.
    Biochem Biophys Res Commun; 2018 Jan 22; 495(4):2649-2656. PubMed ID: 29278707
    [Abstract] [Full Text] [Related]

  • 8. Chlorogenic acid alleviated liver fibrosis in methionine and choline deficient diet-induced nonalcoholic steatohepatitis in mice and its mechanism.
    Miao H, Ouyang H, Guo Q, Wei M, Lu B, Kai G, Ji L.
    J Nutr Biochem; 2022 Aug 22; 106():109020. PubMed ID: 35472433
    [Abstract] [Full Text] [Related]

  • 9. Placental extract ameliorates liver fibrosis in a methionine- and choline-deficient diet-induced mouse model of non-alcoholic steatohepatitis.
    Yamauchi A, Tone T, Toledo A, Igarashi K, Sugimoto K, Miyai H, Deng D, Nakamura J, Lim HS, Kaku T, Hirano E, Shindo T.
    Biomed Res; 2020 Aug 22; 41(1):1-12. PubMed ID: 32092735
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Dynamic alterations in the gut microbiota and metabolome during the development of methionine-choline-deficient diet-induced nonalcoholic steatohepatitis.
    Ye JZ, Li YT, Wu WR, Shi D, Fang DQ, Yang LY, Bian XY, Wu JJ, Wang Q, Jiang XW, Peng CG, Ye WC, Xia PC, Li LJ.
    World J Gastroenterol; 2018 Jun 21; 24(23):2468-2481. PubMed ID: 29930468
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cyclooxygenase-2 expression in hepatocytes attenuates non-alcoholic steatohepatitis and liver fibrosis in mice.
    Motiño O, Agra N, Brea Contreras R, Domínguez-Moreno M, García-Monzón C, Vargas-Castrillón J, Carnovale CE, Boscá L, Casado M, Mayoral R, Valdecantos MP, Valverde ÁM, Francés DE, Martín-Sanz P.
    Biochim Biophys Acta; 2016 Sep 21; 1862(9):1710-23. PubMed ID: 27321932
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Transcriptional repression of SIRT1 by protein inhibitor of activated STAT 4 (PIAS4) in hepatic stellate cells contributes to liver fibrosis.
    Sun L, Fan Z, Chen J, Tian W, Li M, Xu H, Wu X, Shao J, Bian Y, Fang M, Xu Y.
    Sci Rep; 2016 Jun 21; 6():28432. PubMed ID: 27323886
    [Abstract] [Full Text] [Related]

  • 18. Sorafenib reduces steatosis-induced fibrogenesis in a human 3D co-culture model of non-alcoholic fatty liver disease.
    Romualdo GR, Da Silva TC, de Albuquerque Landi MF, Morais JÁ, Barbisan LF, Vinken M, Oliveira CP, Cogliati B.
    Environ Toxicol; 2021 Feb 21; 36(2):168-176. PubMed ID: 32918399
    [Abstract] [Full Text] [Related]

  • 19. Epigallocatechin gallate attenuated non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet.
    Ding Y, Sun X, Chen Y, Deng Y, Qian K.
    Eur J Pharmacol; 2015 Aug 15; 761():405-12. PubMed ID: 25967348
    [Abstract] [Full Text] [Related]

  • 20. Protective effect of isochlorogenic acid B on liver fibrosis in non-alcoholic steatohepatitis of mice.
    Liu X, Huang K, Niu Z, Mei D, Zhang B.
    Basic Clin Pharmacol Toxicol; 2019 Feb 15; 124(2):144-153. PubMed ID: 30180301
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.